Intellia Therapeutics β #6 in Top 10 US Biotech Companies by Pipeline Value | Top10Grid
#6
Intellia Therapeutics
The $2B valuation pioneer of in vivo CRISPR gene editing, delivering gene corrections directly inside the human body. Its NTLA-2001 program for transthyretin amyloidosis showed landmark results with a single infusion.
Comments on "Intellia Therapeutics"
Create a free account or sign in to join the discussion.
Sign in to join the conversation